Regulation of neurotransmitter release from ocular tissues by isoprostanes

Catherine A. Opere, Kim Ford, Min Zhao, Sunny E. Ohia

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Isoprostanes are prostaglandin-like compounds formed in vivo primarily by free radical-catalyzed peroxidation of arachidonic acid independent of the cyclooxygenase enzyme. In addition to being utilized as reliable indicators of oxidative stress, 8-isoprostanes exert pharmacological actions on smooth muscles from several tissues and organs, and they play a role in the release of neurotransmitters from the central and peripheral nervous systems. In the anterior uvea of the eye, 8-isoprostanes produce both excitatory and inhibitory effects on sympathetic neurotransmission in isolated mammalian iris ciliary bodies. Thromboxane (TP) receptors mediate the stimulatory action of isoprostanes on norepinephrine (NE) release from sympathetic nerves. In bovine retina, the 8-isoprostanes exhibit a biphasic regulatory effect on potassium-induced [ 3H]-D-aspartate release, with low concentrations being inhibitory and high concentrations causing on excitatory effect. Excitatory effects of 8-isoprostanes are mediated by TP receptors, while inhibitory responses are mediated by prostaglandin E (EP) receptors. The 8-isoprostanes produce pharmacological actions on sympathetic neurotransmission in mammalian anterior uvea, a response that is species-dependent. In the posterior segment of the eye, 8-isoprostanes elicit a complex response on the retina involving the activation of both prostanoid TP and EP receptors. An effect of isoprostanes on neurotransmitter pools provides new pharmacological target sites for the therapy of some ocular diseases.

Original languageEnglish
Pages (from-to)697-701
Number of pages5
JournalMethods and Findings in Experimental and Clinical Pharmacology
Volume30
Issue number9
DOIs
StatePublished - Nov 2008

Fingerprint

8-epi-prostaglandin F2alpha
Isoprostanes
Thromboxane Receptors
Neurotransmitter Agents
Uvea
Pharmacology
Synaptic Transmission
Prostaglandins
Retina
Posterior Eye Segment
Prostaglandin E Receptors
D-Aspartic Acid
Ciliary Body
Eye Diseases
Peripheral Nervous System
Iris
Prostaglandin-Endoperoxide Synthases
Free Radicals
Smooth Muscle
Norepinephrine

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology

Cite this

Regulation of neurotransmitter release from ocular tissues by isoprostanes. / Opere, Catherine A.; Ford, Kim; Zhao, Min; Ohia, Sunny E.

In: Methods and Findings in Experimental and Clinical Pharmacology, Vol. 30, No. 9, 11.2008, p. 697-701.

Research output: Contribution to journalReview article

@article{93f3e0cc390d47d1aabaf1df5b71f912,
title = "Regulation of neurotransmitter release from ocular tissues by isoprostanes",
abstract = "Isoprostanes are prostaglandin-like compounds formed in vivo primarily by free radical-catalyzed peroxidation of arachidonic acid independent of the cyclooxygenase enzyme. In addition to being utilized as reliable indicators of oxidative stress, 8-isoprostanes exert pharmacological actions on smooth muscles from several tissues and organs, and they play a role in the release of neurotransmitters from the central and peripheral nervous systems. In the anterior uvea of the eye, 8-isoprostanes produce both excitatory and inhibitory effects on sympathetic neurotransmission in isolated mammalian iris ciliary bodies. Thromboxane (TP) receptors mediate the stimulatory action of isoprostanes on norepinephrine (NE) release from sympathetic nerves. In bovine retina, the 8-isoprostanes exhibit a biphasic regulatory effect on potassium-induced [ 3H]-D-aspartate release, with low concentrations being inhibitory and high concentrations causing on excitatory effect. Excitatory effects of 8-isoprostanes are mediated by TP receptors, while inhibitory responses are mediated by prostaglandin E (EP) receptors. The 8-isoprostanes produce pharmacological actions on sympathetic neurotransmission in mammalian anterior uvea, a response that is species-dependent. In the posterior segment of the eye, 8-isoprostanes elicit a complex response on the retina involving the activation of both prostanoid TP and EP receptors. An effect of isoprostanes on neurotransmitter pools provides new pharmacological target sites for the therapy of some ocular diseases.",
author = "Opere, {Catherine A.} and Kim Ford and Min Zhao and Ohia, {Sunny E.}",
year = "2008",
month = "11",
doi = "10.1358/mf.2008.30.9.1323495",
language = "English",
volume = "30",
pages = "697--701",
journal = "Methods and Findings in Experimental and Clinical Pharmacology",
issn = "0379-0355",
publisher = "Prous Science",
number = "9",

}

TY - JOUR

T1 - Regulation of neurotransmitter release from ocular tissues by isoprostanes

AU - Opere, Catherine A.

AU - Ford, Kim

AU - Zhao, Min

AU - Ohia, Sunny E.

PY - 2008/11

Y1 - 2008/11

N2 - Isoprostanes are prostaglandin-like compounds formed in vivo primarily by free radical-catalyzed peroxidation of arachidonic acid independent of the cyclooxygenase enzyme. In addition to being utilized as reliable indicators of oxidative stress, 8-isoprostanes exert pharmacological actions on smooth muscles from several tissues and organs, and they play a role in the release of neurotransmitters from the central and peripheral nervous systems. In the anterior uvea of the eye, 8-isoprostanes produce both excitatory and inhibitory effects on sympathetic neurotransmission in isolated mammalian iris ciliary bodies. Thromboxane (TP) receptors mediate the stimulatory action of isoprostanes on norepinephrine (NE) release from sympathetic nerves. In bovine retina, the 8-isoprostanes exhibit a biphasic regulatory effect on potassium-induced [ 3H]-D-aspartate release, with low concentrations being inhibitory and high concentrations causing on excitatory effect. Excitatory effects of 8-isoprostanes are mediated by TP receptors, while inhibitory responses are mediated by prostaglandin E (EP) receptors. The 8-isoprostanes produce pharmacological actions on sympathetic neurotransmission in mammalian anterior uvea, a response that is species-dependent. In the posterior segment of the eye, 8-isoprostanes elicit a complex response on the retina involving the activation of both prostanoid TP and EP receptors. An effect of isoprostanes on neurotransmitter pools provides new pharmacological target sites for the therapy of some ocular diseases.

AB - Isoprostanes are prostaglandin-like compounds formed in vivo primarily by free radical-catalyzed peroxidation of arachidonic acid independent of the cyclooxygenase enzyme. In addition to being utilized as reliable indicators of oxidative stress, 8-isoprostanes exert pharmacological actions on smooth muscles from several tissues and organs, and they play a role in the release of neurotransmitters from the central and peripheral nervous systems. In the anterior uvea of the eye, 8-isoprostanes produce both excitatory and inhibitory effects on sympathetic neurotransmission in isolated mammalian iris ciliary bodies. Thromboxane (TP) receptors mediate the stimulatory action of isoprostanes on norepinephrine (NE) release from sympathetic nerves. In bovine retina, the 8-isoprostanes exhibit a biphasic regulatory effect on potassium-induced [ 3H]-D-aspartate release, with low concentrations being inhibitory and high concentrations causing on excitatory effect. Excitatory effects of 8-isoprostanes are mediated by TP receptors, while inhibitory responses are mediated by prostaglandin E (EP) receptors. The 8-isoprostanes produce pharmacological actions on sympathetic neurotransmission in mammalian anterior uvea, a response that is species-dependent. In the posterior segment of the eye, 8-isoprostanes elicit a complex response on the retina involving the activation of both prostanoid TP and EP receptors. An effect of isoprostanes on neurotransmitter pools provides new pharmacological target sites for the therapy of some ocular diseases.

UR - http://www.scopus.com/inward/record.url?scp=62649110352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62649110352&partnerID=8YFLogxK

U2 - 10.1358/mf.2008.30.9.1323495

DO - 10.1358/mf.2008.30.9.1323495

M3 - Review article

C2 - 19229378

AN - SCOPUS:62649110352

VL - 30

SP - 697

EP - 701

JO - Methods and Findings in Experimental and Clinical Pharmacology

JF - Methods and Findings in Experimental and Clinical Pharmacology

SN - 0379-0355

IS - 9

ER -